# US 2015/0105331 A1 · High-purity cyclopeptide crystal as well as preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105331 A1
- Document ID: US20150105331A1
- Status: Published application
- Kind: A1
- Application number: 14/389,352
- Filed: 2013-03-29
- Published: 2015-04-16
- Earliest claimed: 2012-03-30
- Assignees: Shanghai Techwell Biopharmaceutical Co., Ltd.
- Applicants: Shanghai Techwell Biopharmaceutical Co., Ltd.
- Inventors: Shidong Liu; Zhaoli Zhang; Xiusheng Wang; Xiao Zhang; Zhijun Tang; Xiaoming Ji
- Web page: https://patentgrep.com/patent/US20150105331A1

## CPC

- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- A61P 31/10: Antimycotics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal.

## Claims

### Claim 1

A cyclopeptide comprising one or more compounds selected from the group consisting of:
crystal A of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal A shows characteristic peaks at the following 2θ angles: 7.1±0.2, 8.0±0.2, 14.7±0.2, 16.8±0.2, 18.9±0.2, 20.3±0.2, 21.1±0.2;
crystal B of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal B shows characteristic peaks at the following 2θ angles: 7.3±0.2°, 11.9±0.2°, 12.8±0.2°, 16.8±0.2°, 19.6±0.2°, 21.1±0.2°, 22.1±0.2°, 22.8±0.2°, 24.3±0.2°, 25.4±0.2°;
crystal C of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal C shows characteristic peaks at the following 2θ angles: 8.6±0.2°, 11.9±0.2°;
crystal D of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal D shows characteristic peaks at the following 2θ angles: 5.6±0.2°, 14.4±0.2°, 19.8±0.2°, 22.7±0.2°, 23.0±0.2°, 23.9±0.2°;
crystal E of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal E shows characteristic peaks at the following 2θ angles: 9.7±0.2°, 19.8±0.2°, 23.0±0.2°;
crystal F of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal F shows characteristic peaks at the following 2θ angles: 7.0±0.2°, 7.9±0.2°, 12.6±0.2°, 14.1±0.2°, 18.5±0.2°, 20.6±0.2°, 21.6±0.2°, 35.6±0.2°;
crystal G of cyclopeptide of formula I, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt, and X-ray powder diffraction pattern (XRPD) of said crystal G shows characteristic peaks at the following 2θ angles: 7.3±0.2°, 19.8±0.2°, 21.1±0.2°.

### Claim 2 (depends on 1)

The cyclopeptide of claim 1, wherein X-ray powder diffraction pattern (XRPD) of said crystal A further shows characteristic peaks at the following 2θ angles: 7.3±0.2, 11.9±0.2, 12.3±0.2, 16.1±0.2, 18.5±0.2, 19.6±0.2, 22.1±0.2, 22.8±0.2, 23.1±0.2, 24.3±0.2, 25.4±0.2, 28.3±0.2, 33.5±0.2.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The cyclopeptide of claim 1, wherein X-ray powder diffraction pattern (XRPD) of said crystal D further shows characteristic peaks at the following 2θ angles: 7.4±0.2°, 8.2±0.2°, 9.7±0.2°, 12.2±0.2°, 16.5±0.2°, 18.6±0.2°, 22.3±0.2°, 28.2±0.2°.

### Claim at position 5

7-8. (canceled)

### Claim 9 (depends on 1)

The cyclopeptide of claim 1, comprising crystal F, wherein X-ray powder diffraction pattern (XRPD) of said crystal F further shows characteristic peaks at the following 2θ angles: 7.3±0.2°, 12.1±0.2°, 14.4±0.2°, 16.7±0.2°, 19.8±0.2°, 21.1±0.2°, 22.9±0.2°, 23.6±0.2°, 24.9±0.2°, 30.7±0.2°.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method of preparing crystal A of the cyclopeptide of claim 1, said method comprising:
(a) dissolving the compound of formula I into water or aqueous organic solvent (i), and controlling pH of the solution comprising the compound of formula I;
(b) obtaining crystal A of the cyclopeptide by reducing the temperature and/or adding organic solvent (i);
wherein organic solvent (i) is one or more selected from the group consisting of methanol, ethanol, n-propanol, and isopropanol.

### Claim 12 (depends on 11)

The method according to claim 11, wherein, in step (a), pH of the solution is controlled at 2.0-5.0.

### Claim 13 (depends on 11)

The method according to claim 11, wherein, in step (a), the solution comprises 50 to 500 mg/ml of compound of formula I, based on the total volume of the solution in step (a).

### Claim 14 (depends on 1)

A method of preparing crystals B and/or crystal C of the cyclopeptide of claim 1, said method comprising:
(a) dissolving the compound of formula I into water or aqueous organic solvent (i), and controlling pH of the solution comprising the compound of formula I;
(b) obtaining crystal A of the cyclopeptide by reducing the temperature and/or adding organic solvent (i);
(c) vacuum-drying crystal A obtained in step (b) and controlling the moisture content, so as to give the crystal B or C;
wherein organic solvent (i) is one or more selected from the group consisting of ethanol, n-propanol, and isopropanol.

### Claim 15 (depends on 14)

The method according to claim 14, wherein crystal C is obtained by controlling the moisture content at less than 6%, and crystal B is obtained by controlling the moisture content at 6%-12%.

### Claim 16 (depends on 1)

A method of preparing crystal D of claim 1, said method comprising:
(a) dissolving the compound of formula I into water or aqueous methanol, and controlling pH of the solution comprising the compound of formula I;
(b) obtaining crystal D of the cyclopeptide by reducing the temperature and/or adding methanol.

### Claim 17 (depends on 1)

A method of preparing crystal E of the cyclopeptide of claim 1, said method comprising:
(a) dissolving the compound of formula I into water or aqueous methanol, and controlling pH of the solution comprising the compound of formula I;
(b) obtaining crystal D of the cyclopeptide by reducing the temperature and/or adding methanol;
(c) vacuum-drying crystal D obtained in step (b) and controlling the moisture content, so as to give crystal E.

### Claim 18 (depends on 1)

A method of preparing crystal F of the cyclopeptide of claim 1, said method comprising:
(a) dissolving the compound of formula I into water, and controlling pH of the solution comprising the compound of formula I;
(b) obtaining crystal F of the cyclopeptide by reducing the temperature.

### Claim 19 (depends on 1)

A method of preparing crystal G of the cyclopeptide of claim 1, said method comprising:
(a) dissolving the compound of formula I into water, and controlling pH of the solution comprising the compound of formula I;
(b) obtaining crystal F of the cyclopeptide by reducing the temperature;
(c) vacuum-drying crystal F obtained in step (b) and controlling the moisture content, so as to give crystal G.

### Claim 20 (depends on 1)

Use of the crystal(s) of the cyclopeptide according to claim 1 for preparing the compound of formula II, wherein R represents H or a cation capable of forming a pharmaceutically acceptable salt:
and/or for preparing medicaments for treating fungal infections.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A pharmaceutical composition comprising the crystal of the cyclopeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 1)

A method of preparing a pharmaceutical composition, said method comprising:
mixing one or more crystal(s) of the cyclopeptide of claim 1 with a pharmaceutically acceptable carrier, so as to obtain a pharmaceutical composition.

### Claim 24

A cyclopeptide composition comprising one or more compounds selected from the group consisting of the following: crystal A of the cyclopeptide, crystal B of the cyclopeptide, crystal C of the cyclopeptide.

### Claim 25

A cyclopeptide composition comprising crystal D of the cyclopeptide and crystal E of the cyclopeptide.

### Claim 26

A cyclopeptide composition comprising crystal F of the cyclopeptide and crystal G of the cyclopeptide.
